MMMalihe Mohammadi

Malihe Mohammadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Malihe Mohammadi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Heavy metals in henna leaves ( Lawsonia inermis ) from Sistan and Baluchestan Province, Iran: dermal exposure and toxicological risk assessment

    by Romina Keikha, Malihe Mohammadi

    Background: Lawsonia inermis L., commonly known as henna has been used for cosmetic and medicinal purposes since ancient times. Objective: This study evaluated the potential health risks associated with arsenic (As), lead (Pb), and zinc (Zn) in henna leaves collected from Dalgan and Iranshahr, Sistan and Baluchestan Province, Iran. Methods: ...

  • Open Access

    Association of TGFA gene polymorphisms (rs11466297 and rs3732248) with polycystic ovary syndrome (PCOS): a case-control study

    by Fatemeh Keykha, Malihe Mohammadi, Marzieh Ghasemi, Ramin Saravani

    Polycystic ovary syndrome (PCOS) is a complicated endocrine condition that causes ovarian dysfunction, metabolic problems, and hormonal irregularities. Gen

  • Open Access

    Safety and efficacy of the Oxford-AstraZeneca vaccine against SARS-CoV-2 after 2nd and 3rd dose in adults: a cross-sectional study

    by Shahrbanoo Sedigh Sarooni, Malihe Mohammadi, Seyed Mohammad Riahi

    Safety and efficacy of the Oxford-AstraZeneca vaccine against SARS-CoV-2 after 2nd and 3rd dose in adults: a cross-sectional study. Background: The rapid global spread of the coronavirus SARS-CoV-2 and the lack of established therapeutic choices led to development of several vac...

  • Open Access

    Prevalence of latent autoimmune diabetes in adults and insulin resistance: a systematic review and meta-analysis

    by Malihe Mohammadi

    Latent autoimmune diabetes in adults is a form of diabetes that progresses slowly and is controlled by diet and oral glucose-lowering medications before insulin is required. The aim of the present study was to evaluate the prevalence of latent autoimmune diabetes in adults. The present study was conducted based on PRISMA 2020-27-item checklist. To find the studies conducted in line with the purpose of the study, PubMed, Web of Science, Scopus, Science Direct, Web of Knowledge, EBSCO, Wiley, ISI, Elsevier, Embase databases and Google Scholar search engine were reviewed from 2013 to August 2023. Meta-analysis was performed using effect size with 95% confidence interval. Data analysis was done using STATA/MP. v17 software. The present study was carried out based on the PRISMA 2020 27-point checklist. To find out which studies were carried out in accordance with the purpose of the study, from 2013 to August, the databases PubMed, Web of Science, Scopus, Science Direct, Web of Knowledge, EBSCO, Wiley, ISI, Elsevier, Embase and the search engine Google Scholar reviewed 2023. Meta-analysis was performed using effect size with 95% confidence interval. Data analysis was carried out using STATA/MP. v17 software. The overall prevalence of Latent autoimmune diabetes of adults was found to be 7% (95%CI 0–20). Subgroup analysis of Latent autoimmune diabetes of adults in the context of geographic regions showed a higher prevalence in North America (15%) and South East Asia (5%). Since the identification of Latent autoimmune diabetes of adult patients with other forms of diabetes is misdiagnosed due to the combination of phenotypic features with T1D and T2D, studying its prevalence is of great importance.


  • Prevalence and Metabolic Characteristics of Patients with Latent Autoimmune Diabetes in Adults: A Cross-Sectional Study

    by Mahdieh Mehranpoor, Malihe Mohammadi, Milad Lagzian

    Objective: To evaluate the frequency of autoantibodies to glutamic acid decarboxylase-65 (GADA) and tyrosine phosphatase (IA-2A) in adult patients diagnosed with type 2 diabetes (T2D) and its associated characteristics, in particular those that related to metabolic syndrome. Materials and methods: In this cross-sectional study, autoantibodies to GADA and IA-2A were measured in 384 adult patients with T2D. Assays for autoantibodies were conducted using ELISA kits. The sociodemographic, clinical, and metabolic characteristics of islet autoantibody-positive and negative participants were then compared. SPSS software was used for data analysis and p < 0.05 was selected as a significant level. Results: Thirty two (8.3%) participants were positive for at least one islet autoantibody. The prevalence of GADA and IA-2A were reported 6.3% and 2.3% respectively, and one patient had both antibodies together. Autoantibody-positive patients were significantly younger (p < 0.001), had lower median age at diagnosis (p = 0.010), mean body mass index (BMI) (p = 0.004), waist circumference (WC) (p = 0.033), total cholesterol (p = 0.020), triglycerides (p = 0.041), C-peptide (p < 0.001) and prevalence of metabolic syndrome (p < 0.001) and higher fasting blood glucose (FBG) (p = 0.046), glycated hemoglobin (HbA1c) levels (p = 0.035) and need for insulin therapy (p < 0.001) than patients with T2D. Sex distribution, blood pressure levels and family history of diabetes were similar in the two groups. Conclusions: The prevalence of LADA in the studied population was 8.3%. LADA should be suspected in leaner patients with T2D with worse glycemic control, low C-peptide level and without metabolic syndrome. Antibody screening is recommended to discriminate of LADA and to help better control of glycemic profile. Objective: To evaluate the frequency of autoantibodies to glutamic acid decarboxylase-65 (GADA) and tyrosine phosphatase (IA-2A) in adult patients diagnosed with type 2 diabetes (T2D) and its associated characteristics, in particular those that related to metabolic syndrome. Materials and methods: In this cross-sectional study, autoantibodies to GADA and IA-2A were measured in 384 adult patients with T2D. Assays for autoantibodies were conducted using ELISA kits. The sociodemographic, clinical, and metabolic characteristics of islet autoantibody-positive and negative participants were then compared. SPSS software was used for data analysis and p < 0.05 was selected as a significant level. Results: Thirty two (8.3%) participants were positive for at least one islet autoantibody. The prevalence of GADA and IA-2A were reported 6.3% and 2.3% respectively, and one patient had both antibodies together. Autoantibody-positive patients were significantly younger (p < 0.001), had lower median age at diagnosis (p = 0.010), mean body mass index (BMI) (p = 0.004), waist circumference (WC) (p = 0.033), total cholesterol (p = 0.020), triglycerides (p = 0.041), C-peptide (p < 0.001) and prevalence of metabolic syndrome (p < 0.001) and higher fasting blood glucose (FBG) (p = 0.046), glycated hemoglobin (HbA1c) levels (p = 0.035) and need for insulin therapy (p < 0.001) than patients with T2D. Sex distribution, blood pressure levels and family history of diabetes were similar in the two groups. Conclusions: The prevalence of LADA in the studied population was 8.3%. LADA should be suspected in leaner patients with T2D with worse glycemic control, low C-peptide level and without metabolic syndrome. Antibody screening is recommended to discriminate of LADA and to help better control of glycemic profile.


  • Open Access

    Prevalence of Islet Cell Autoantibodies in Adult Patients Followed for Type 2 Diabetes Mellitus: A Cross-sectional Study

    by Rahime Naroei, Mahdieh Mehranpoor, Malihe Mohammadi, Milad Lagzian

    Introduction: This study was aimed to assess the prevalence of islet cell autoantibodies (ICAs) in type 2 diabetes mellitus (T2DM) patients and to compare some clinical and metabolic markers between ICA-negative and ICA- positive groups in South Khorasan province, East of Iran.Methods: In this cross-sectional study, 384 T2DM patients, all over 30 years old, were selected. None of the patients needed insulin therapy for at least 6 months following diagnosis. Demographic data including gender, age, age at diagnosis, disease duration, health status, family history of diabetes, body mass index (BMI) and treatment type were collected from all subjects. ICA assays were conducted using commercial enzyme-linked immunosorbent assay (ELISA) kits. In addition, blood pressure, as well as cholesterol, serum C-peptide and HbA1c levels were compared between ICA-negative and ICA-positive groups. Data were analyzed using SPSS software and P < 0.05 was considered as statistically significant.Results: ICA was detected in 1.30% of all diabetic patients. Compared with ICA-negative patients, ICA-positive subjects had significantly lower median age (P = 0.000), lower median disease duration (P = 0.001), lower C-peptide level (P = 0.006) and worse glycaemic control (HbA1c, P = 0.040). Furthermore, autoantibody-positive patients had more need for insulin therapy (P = 0.022). No significant correlation was found between ICA prevalence and family history of diabetes (P = 0.262), mean fasting blood glucose (FBG) (P = 0.282), BMI (P = 0.054), blood pressure (P = 0.070) as well as cholesterol levels (P = 0.888).Conclusion: Autoantibody screening is recommended in T2DM patients, especially non-obese patients under 40 years old, showing worse glycaemic control.

  • Epigenetics changes affecting L-asparaginase therapy in human leukemia: a mini review

    by Solmaz Moosavi, Malihe Mohammadi, Milad Lagzian